terazosin   

GtoPdb Ligand ID: 7302

Synonyms: ABBOTT-45975 | Hytrin®
terazosin is an approved drug (FDA (1987))
Compound class: Synthetic organic
Comment: Postsynaptic α1-adrenoceptor inhibitor.
Marketed formulations may contain terazosin hydrochloride (PubChem CID 44383).
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: terazosin

2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 103.77
Molecular weight 387.19
XLogP 2.32
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1
Isomeric SMILES COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1
InChI InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)
InChI Key VCKUSRYTPJJLNI-UHFFFAOYSA-N
No information available.
Summary of Clinical Use
Used to treat hypertension (not recommended as a first-line therapy) and urinary retention caused by benign prostatic hyperplasia (BPH).
Mechanism Of Action and Pharmacodynamic Effects
Terazosin is a selective α1-adrenoceptor antagonist. It blocks the action of endogenous adrenaline on smooth muscle cells within walls of the bladder and blood vessels. The drug has a relaxation effect on bladder wall musculature and blood vessels. This effect on peripheral blood vessel walls reduces blood pressure. Terazosin relaxes prostatic and urethral smooth muscle thereby improving urinary tract flow in BPH patients.
External links